Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Sagimet Biosciences Inc Series A (SGMT)

$7.72 -0.18 (-2.28%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	257.42M
Revenue (ttm)	0.00
Net Income (ttm)	-51.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,291,200
Avg Vol	1,539,080
Day's Range	N/A - N/A
Shares Out	32.59M
Stochastic %K	55%
Beta	3.60
Analysts	Strong Sell
Price Target	$26.58

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

Whiskeyunderthebed May. 5 at 4:06 PM

$SGMT repeat of yesterday-stealing shares again.

1 · Reply

perpetbill May. 5 at 2:49 PM

$SGMT when could the Chinese authorities rule on acne?

1 · Reply

Whiskeyunderthebed May. 5 at 12:52 PM

$SGMT

1 · Reply

Whiskeyunderthebed May. 4 at 8:06 PM

$SGMT In fact they were stealing shares today...

0 · Reply

Whiskeyunderthebed May. 4 at 5:58 PM

$SGMT this is getting fudged today-when bios are ripping.

0 · Reply

anachartanalyst May. 4 at 4:02 PM

$SGMT https://anachart.com/wp-content/uploads/2026/05/1777910512_soc-img.jpg

0 · Reply

rational1 May. 4 at 3:30 PM

$SGMT Canaccord raise price target to $49.

1 · Reply

SuperGreenToday May. 4 at 11:35 AM

$SGMT Share Price: $7.61 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.34 – $1.65 Target Zone: $2.36 – $2.88 Potential Upside: 66% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Biostock May. 4 at 1:03 AM

$ATOM Running, keep $SGMT $DAIO $RILY on your watch for similar move.

0 · Reply

TrayDURRRR May. 2 at 10:14 AM

$SGMT qhen you see outrageous price targets and a declining price it usually means they are trying to prop it up for an offering

1 · Reply

Sagimet Biosciences Transcript: Status update

Apr 27, 2026, 1:48 PM EDT - 8 days ago

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Apr 27, 2026, 7:15 AM EDT - 9 days ago

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Apr 27, 2026, 7:00 AM EDT - 9 days ago

Sagimet Biosciences Provides Strategic and Corporate Updates

Apr 20, 2026, 7:00 AM EDT - 16 days ago

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Apr 6, 2026, 7:00 AM EDT - 4 weeks ago

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2026, 7:30 AM EDT - 2 months ago

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 1:00 PM EDT - 2 months ago

Sagimet Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 1:10 PM EST - 2 months ago

Sagimet Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 11:20 AM EST - 2 months ago

Sagimet Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 2 months ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Feb 11, 2026, 10:00 AM EST - 2 months ago

Sagimet Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 3 months ago

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Feb 2, 2026, 7:00 AM EST - 3 months ago

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Jan 29, 2026, 6:00 AM EST - 3 months ago

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Jan 27, 2026, 3:00 AM EST - 3 months ago

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Jan 8, 2026, 7:00 AM EST - 4 months ago

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Dec 18, 2025, 7:00 AM EST - 4 months ago

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Dec 10, 2025, 7:03 AM EST - 5 months ago

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Dec 10, 2025, 4:15 AM EST - 5 months ago

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Dec 9, 2025, 4:05 PM EST - 5 months ago

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2025, 12:55 PM EST - 5 months ago

Sagimet Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 7:00 AM EST - 5 months ago

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 10, 2025, 11:30 AM EST - 6 months ago

Sagimet Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:00 AM EST - 6 months ago

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Oct 24, 2025, 7:00 AM EDT - 6 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 21, 2025, 7:00 AM EDT - 7 months ago

Sagimet Biosciences Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 14, 2025, 6:00 AM EDT - 7 months ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 7, 2025, 7:00 AM EDT - 7 months ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Sep 17, 2025, 7:00 AM EDT - 8 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 10, 2025, 7:00 AM EDT - 8 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 3, 2025, 1:35 PM EDT - 8 months ago

Sagimet Biosciences Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 7:00 AM EDT - 9 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 13, 2025, 7:30 AM EDT - 9 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 9 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 16, 2025, 2:00 PM EDT - 11 months ago

Sagimet Biosciences Transcript: KOL Event

Jun 9, 2025, 7:00 AM EDT - 11 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 4, 2025, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event

May 22, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 8, 2025, 6:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Dec 3, 2024, 10:00 AM EST - 1 year ago

Sagimet Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 8:00 PM EST - 1 year ago

Sagimet Biosciences Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 7, 2024, 2:30 PM EDT - 1 year ago

Sagimet Biosciences Transcript: 8th Annual MASH Investor Conference

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 17, 2024, 9:10 AM EDT - 1 year ago

Sagimet Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 10, 2024, 11:00 AM EDT - 1 year ago

Sagimet Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Study Update

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 2 years ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Investor & Analyst Day 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 2 years ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 2 years ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Transcript: Leerink Partners Global Biopharma Conference 2024

Jan 25, 2024, 8:58 PM EST - 2 years ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 23, 2024, 5:45 PM EST - 2 years ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Whiskeyunderthebed May. 5 at 4:06 PM

$SGMT repeat of yesterday-stealing shares again.

1 · Reply

perpetbill May. 5 at 2:49 PM

$SGMT when could the Chinese authorities rule on acne?

1 · Reply

Whiskeyunderthebed May. 5 at 12:52 PM

$SGMT

1 · Reply

Whiskeyunderthebed May. 4 at 8:06 PM

$SGMT In fact they were stealing shares today...

0 · Reply

Whiskeyunderthebed May. 4 at 5:58 PM

$SGMT this is getting fudged today-when bios are ripping.

0 · Reply

anachartanalyst May. 4 at 4:02 PM

$SGMT https://anachart.com/wp-content/uploads/2026/05/1777910512_soc-img.jpg

0 · Reply

rational1 May. 4 at 3:30 PM

$SGMT Canaccord raise price target to $49.

1 · Reply

SuperGreenToday May. 4 at 11:35 AM

0 · Reply

Biostock May. 4 at 1:03 AM

$ATOM Running, keep $SGMT $DAIO $RILY on your watch for similar move.

0 · Reply

TrayDURRRR May. 2 at 10:14 AM

$SGMT qhen you see outrageous price targets and a declining price it usually means they are trying to prop it up for an offering

1 · Reply

Biostock May. 2 at 2:12 AM

$SGMT has a first-line acne drug with a potential TAM exceeding $1 billion annually and holds global rights excluding China. Despite this, its market capitalization is only about half of the projected yearly sales. In contrast, $CELC has a second-line cancer drug partnered with $PFE , with a possible TAM under $2.5 billion, yet its market cap exceeds $6 billion. $QQQ $SPY

0 · Reply

Biostock May. 1 at 8:12 PM

$ATOM The irony. No one wanted it when i was screaming, now there is a stampede. The next big movers on my list $SGMT $DAIO $RILY

1 · Reply

StreetwiseReports May. 1 at 6:38 PM

Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential https://ow.ly/4wp550YTzjy Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences ( $SGMT ), implying roughly 249% upside.

0 · Reply

flashmem May. 1 at 6:18 PM

$SGMT Shorts back in total control. Just no support.

0 · Reply

rational1 May. 1 at 5:08 PM

$SGMT Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential

0 · Reply

rational1 May. 1 at 5:08 PM

$SGMT Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating Friday, May 01, 2026 10:37:58 AM ET

0 · Reply

Biostock May. 1 at 4:33 PM

$SGMT Market cap should be at 4 times of the premium to current market cap for ACNE drug that will rack in over $1 billion dollars a year in sales after clearing FDA in coming years. $XBI $QQQ $SPY

0 · Reply

Biostock May. 1 at 3:54 PM

$KOPN $DAIO $RILY $ATOM.X $SGMT

0 · Reply

rational1 May. 1 at 2:42 PM

$SGMT

1 · Reply

Whiskeyunderthebed May. 1 at 2:32 PM

$SGMT According to Harper, sapienic acid levels were reduced by “about 90%” by day 15 and remained reduced throughout the study period.

0 · Reply

Whiskeyunderthebed May. 1 at 2:29 PM

$SGMT have a look at the borrowed shares for the week-quite heavy today. https://www.iborrowdesk.com/report/SGMT

0 · Reply

delmarloop May. 1 at 2:27 PM

$SGMT I like my Sagimet well churned

0 · Reply

1.0.0